To investigate the molecular changes, mutations, and signaling pathways that characterize the initial steps of prostate cancer metastasis to the lymph nodes, we analyzed 19 discrete lymph node (LN) metastases, 97 primary tumor foci, 39 benign lymph nodes, and 10 normal adjacent prostate tissue samples from 43 patients enrolled in a clinical trial (<a href="https://www.clinicaltrials.gov/study/NCT01808222?cond=NCT01808222&#x26;rank=1">NCT01808222</a>) of extended lymphadenectomy and metastasis excision guided by [18F]-fluciclovine PET imaging for high risk, newly diagnosed prostate cancer conducted at Emory University. These patients fell within high or very high-risk groups (T3a, Gleason score 8-10, or PSA greater than 20 ng/ml). Of these patients, 16 had LN metastases at least 4 mm in diameter, and 20 patients had no metastases. For metastatic patients, we performed RNA and Whole Exome Sequencing (WES) on three primary tumor foci, one benign LN, and all LN metastases greater than 4mm in diameter. For non-metastatic patients, we sequenced two primary tumor foci and one benign LN. In total, RNAseq was performed on 165 tissue samples from 43 patients, and WES was performed on 137 samples from 35 patients.

Genomic Analysis of Prostate Tumor Heterogeneity in Metastasis

Prostatic Neoplasms study with RNA-Seq, SNP/CNV Genotypes (NGS) + 2 more data on dbGaP (43 participants)

Genomic Analysis of Prostate Tumor Heterogeneity in Metastasis

Description

Applying For Access

Summary